Comparative Pharmacology
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELESTONE SOLUSPAN versus STERANE.
CELESTONE SOLUSPAN vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing immune cell activity.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
1-2 mL (6-12 mg/mL betamethasone acetate and betamethasone sodium phosphate) intramuscularly or intralesionally, repeat every 1-4 weeks as needed.
100 mg orally every 12 hours
None Documented
None Documented
Plasma terminal half-life: betamethasone phosphate ~3-5 hours; betamethasone acetate ~6-8 hours. Clinical duration extended due to ester hydrolysis and depot effect (up to 7-14 days for IM injection).
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal: ~65% as metabolites and unchanged drug; biliary/fecal: ~20%; remainder via other pathways.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid